Annex № 9 To Art. 33, par. 1, it.3 of Ordinance № 2 from 17.09.2003 And Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014

INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED DURING THE FIRST QUARTER OF 2021 OF "SOPHARMA" AD

1.1. No change in the persons controlling the Company.

1.2. (Annulled – State Gazette, issue 63 from 2016).

1.3. (Annulled – State Gazette, issue 63 from 2016).

1.4. (Annulled – State Gazette, issue 63 from 2016).

1.5. (Annulled – State Gazette, issue 63 from 2016).

1.6. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.

1.7. No acquisition, use or disposition of high-value assets.

1.8. No decision on conclusion, termination and cancellation of joint venture agreements.

1.9. (Annulled – State Gazette, issue 82 from 2007).

1.10. Change of the auditors of the company - At the Regular General Meeting of Shareholders of "SOPHARMA" AD, held on June 7, 2019, the auditing company "BAKER TILLY KLITOU AND PARTNERS" OOD, based in Sofia, Acad. "Ivan Evst. Geshov " 104, for a registered auditor for inspection and certification of the Annual Financial Statements of the Company.

1.11. (Annulled – State Gazette, issue 63 from 2016).

1.12. (Annulled – State Gazette, issue 63 from 2016).

1.13. (Annulled – State Gazette, issue 63 from 2016).

1.14. (Annulled – State Gazette, issue 63 from 2016).

1.15. (Annulled – State Gazette, issue 63 from 2016).

1.16. (Annulled – State Gazette, issue 63 from 2016).

1.17 (Annulled – State Gazette, issue 63 from 2016).

1.18. (Annulled – State Gazette, issue 63 from 2016).

1.19. (Annulled – State Gazette, issue 63 from 2016).

1.20. (Annulled – State Gazette, issue 63 from 2016).

1.21. (Annulled – State Gazette, issue 63 from 2016) No conclusion or performance of essential contracts, which do not relate to the ordinary business of the Company.

1.22. (Annulled – State Gazette, issue 63 from 2016).

1.23. (Annulled – State Gazette, issue 63 from 2016).

1.24. (Annulled – State Gazette, issue 63 from 2016).

1.25. (Annulled – State Gazette, issue 63 from 2016).

1.26. (Annulled – State Gazette, issue 63 from 2016).

1.27. (Annulled – State Gazette, issue 63 from 2016).

1.28. (Annulled – State Gazette, issue 63 from 2016).

1.29. (Annulled – State Gazette, issue 63 from 2016).

This is a translation from Bulgarian of the Preliminary annual individual financial statements

of "Sopharma" AD.

In case of divergence Bulgarian text should prevail.

1.30. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.1.31. Purchase, sale or established pledge of shares in commercial companies by the issuer or its subsidiary.

On 10 March 2021 the Company sold 396,600 of its shares in the capital of "Momina Krepost" AD, as a result of which the share of ownership of "Sopharma" AD became 37.46%. On 15. March 2021 an agreement was concluded between Sopharma AD and Medical Consumables OOD for a common policy in the management of "Momina Krepost" AD through joint exercise of voting rights.

1.32. (Annulled – State Gazette, issue 63 from 2016).

1.33. (Annulled – State Gazette, issue 63 from 2016).

1.34. Other circumstances that the Company considers may be relevant to investors in taking a decision to acquire, sell or continue to hold publicly-traded securities: none.

"Sopharma" AD informs all interested parties that the interim financial statements of the Company as at 31 March 2021 have not been verified by a registered auditor.

/Signature/ Ognian Donev, PhD /Executive Director/